MC3817 |
カタログ番号GC79145
One-Click Copy Product Info
|
MC3817 is a selective DNMT1 inhibitor.
Products are for research use only. Not for human use. We do not sell to patients.
Sample solution is provided at 25 µL, 10mM.
_1-3.$$$39978408@51.jpg');)
_1-9.$$$38538795@65.jpg');)
_1-9.$$$39112701@51.jpg');)
_1-7.$$$37316672@70.jpg');)
_366-372.$$$36198801@70.jpg');)
.$$$38565142@65.jpg');)
_1867-1883.$$$33248023@67.jpg');)
_eads6055.$$$39977546@45.jpg');)
_eadm9805.$$$40080571@45.jpg');)
_eadj3020.$$$39666821@45.jpg');)
_1-20.$$$39757301@28.jpg');)
_1-24.$$$38898113@28.jpg');)
_273-287.$$$36806353@46.jpg');)
_1-16.$$$37156877@44.jpg');)
_1-19.$$$37460805@44.jpg');)
_1291-1307.$$$34518654@46.jpg');)
In Vitro, MC3817 (compound 14) (0.05-100 μM, 48 h) exhibits antiproliferative activity against A549 and H460 (non-small cell and lung cancer), HCT-116 (colon cancer), HeLa (cervical cancer), MDA-MB-231 (triple-negative breast cancer), and U937 (histiocytic lymphoma) cells[1]. MC3817 (2 μM, 24 and 48 h) induces S/G2M phase arrest and triggers apoptotic cell death in HCT-116 cells[1]. MC3817 (0.5-5 μM, 16-48 h) triggers DNA damage and activates the p53/γH2AX pathway, leading to cell-cycle arrest and apoptosis in HCT 116 cells[1]. MC3817 (2.5 μM, 48 h) induces a much higher level of apoptosis in HCT-116 P53 WT cells compared with HCT-116 P53−/− cells [1].
References:
[1]. Zwergel C, et al. Quinoline-Based DNA Methyltransferase Inhibitors Featuring Basic Side Chains: Design, Synthesis, and Insight in Biochemical and Anticancer Cell Properties. J Med Chem. 2025 Nov 27;68(22):23886-23909.
| Cas No. | SDF | ||
| Formula | C33H41Cl4N9O | M.Wt | 721.55 |
| 溶解度 | DMSO: 100 mg/mL (138.59 mM; Need ultrasonic) | Storage | Store at -20°C |
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 1.3859 mL | 6.9295 mL | 13.8591 mL |
| 5 mM | 277.2 μL | 1.3859 mL | 2.7718 mL |
| 10 mM | 138.6 μL | 693 μL | 1.3859 mL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
g
μL
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL saline, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >99.50% Appearance: A solid
- COA (Certificate of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5 (Based on Reviews and 30 reference(s) in Google Scholar.)